Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
YD BioYDES -3.54%15 PB Ratio is 57.30 as of Sep. 06, 2026, which is 59% below its 10-year median of 140.46. GuruFocus rates YDES with a GF Score™ of 15/100. The stock has 1 warning sign investors should review. Among 1,218 Biotechnology companies, YD Bio ranks worse than 97.87% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-09-06), YD Bio's share price is $3.61. YD Bio's Book Value per Share for the quarter that ended in Jun. 2026 was $0.06. Hence, YD Bio's PB Ratio of today is 57.30.
Good Sign:
YD Bio Ltd stock PB Ratio (=57.3) is close to 2-year low of 57.3.
The historical rank and industry rank for YD Bio's PB Ratio or its related term are showing as below:
YDES'
s PB Ratio Range Over the Past 10 Years
Min: 57.3 Med: 140.46 Max: 245.85
Current: 57.3
During the past 3 years, YD Bio's highest PB Ratio was 245.85. The lowest was 57.30. And the median was 140.46.
YDES's PB Ratio is ranked worse than 97.87% of 1218
companies
in the Biotechnology industry
Industry Median: 2.995
vs YDES: 57.30
During the past 12 months, YD Bio's average Book Value Per Share Growth Rate was -13.70% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
YD Bio PB Ratio Related Terms
YD Bio PB Ratio Historical Data
* Premium members only.
The historical data trend for YD Bio's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
YD Bio PB Ratio Chart
YD Bio Annual Data
Trend
Dec23
Dec24
Dec25
PB Ratio
0.00
0.00
0.00
YD Bio Semi-Annual Data
Dec23
Dec24
Jun25
Dec25
Jun26
PB Ratio
0.00
0.00
0.00
0.00
35.71
YDES vs TTRX, BCYC, FULC: PB Ratio Comparison
For the Biotechnology subindustry, YD Bio's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
YD Bio PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, YD Bio's PB Ratio distribution charts can be found below:
* The bar in red indicates where YD Bio's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
YD Bio's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
YD Bio (YDES) has a PB Ratio of 57.30 as of Sep. 06, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on YD Bio and its competitors. This is 59% below median its historical median of 140.46. Over the past decade, YD Bio's PB Ratio has ranged from 57.30 to 245.85. According to the industry distribution chart, YD Bio ranks #1192 out of 1218 companies in the Biotechnology industry, placing it in the top 97.9%.
Is YD Bio's PB Ratio too high?
YD Bio's current PB Ratio of 57.30 is 59% below median its 10-year median of 140.46. Over the past 10 years, this metric has ranged from a low of 57.30 to a high of 245.85. The Biotechnology industry median PB Ratio is 3.00. YD Bio's value of 57.30 is 1813.2% above this industry median. Based on the distribution chart, YD Bio ranks #1192 out of 1218 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, YD Bio has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does YD Bio's PB Ratio compare to TTRX and BCYC?
According to the Biotechnology industry distribution chart, YD Bio ranks #1192 out of 1218 companies for PB Ratio. This places YD Bio in the lower half of its industry. The industry median PB Ratio is 3.00. YD Bio's value of 57.30 is 1813.2% above this benchmark. Historically, YD Bio's own PB Ratio has ranged from 57.30 to 245.85 over the past decade. While the company's 10-year median is 140.46 vs. the industry median of 3.00, YD Bio has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 3.00, based on 1,218 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. YD Bio's current PB Ratio of 57.30 is 1813.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on YD Bio and its competitors. For the Biotechnology industry, the median PB Ratio is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. YD Bio's current PB Ratio is 57.30, which is 59% below median its own 10-year median of 140.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is YD Bio stock overvalued right now?
YD Bio (YDES) has a current PB Ratio of 57.30. The current PB Ratio is 57.30, which is 59% below median its 10-year median of 140.46 and 1813.2% above the Biotechnology industry median of 3.00. YD Bio's overall GF Score™ is 15/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For YD Bio (YDES), the current PB Ratio is 57.30 as of Sep. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
YD Bio Ltd is a biotechnology company focused on regulated diagnostics, life science clinical services and healthcare product commercialization. Its operations include DNA methylation-based oncology testing programs in the United States under an LDT framework with CLIA-certified and CAP-accredited laboratory partners. The Company also provides life science distribution and clinical trial supply chain services, including procurement, logistics coordination and compliance-focused support for clinical development programs. It maintains ocular health product commercialization operations in the United States and consumer healthcare distribution activities in Asia. The Company operates in the United States and Taiwan, with Taiwan generating maximum revenue.
15GF Score
Get the complete analysis for YDES
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
YDES has been successfully added to your 
